Researchers have made significant strides in treating Gastrointestinal Stromal Tumors (GIST) with a new drug combination that shows promise in extending progression-free survival (PFS). The combination of bezuclastinib and sunitinib has demonstrated a median PFS of 16.5 months, compared to just 9.2 months for sunitinib alone. This is the first treatment to show a statistically significant advantage over existing therapies for patients who have not responded to prior treatment with imatinib.

This finding is crucial for those battling GIST, a rare type of cancer that can be particularly challenging to treat. The results suggest that people with imatinib-resistant or intolerant GIST could potentially enjoy a longer period without disease progression, which is a vital aspect of maintaining quality of life. The study involved a global, randomized Phase 3 trial, indicating a robust level of evidence for these findings.

While the results are promising, they are based on early-stage data from the Phase 3 PEAK trial, and further validation is needed before widespread clinical application. The full results will be presented at the American Society of Clinical Oncology (ASCO) conference, which could provide more insights into the drug’s effectiveness and safety. As the FDA has accepted the New Drug Application for this treatment, there is cautious optimism that it may soon become available for patients in need.

Source: globenewswire.com